Related Experiment Video
Updated: Mar 1, 2026

Wireless Telemetry Device Implantation in a Fontan Ovine Model for Continuous and Long-Term Hemodynamic Monitoring
Published on: May 2, 2025
Hospital Inpatient Costs for Single Ventricle Patients Surviving the Fontan Procedure
Li Huang1, Chris Schilling1, Kim M Dalziel1
1Centre for Health Policy, The University of Melbourne, Melbourne, VIC, Australia.
Insights
Fontan patients require significant inpatient resources throughout life, with over 40% of pediatric costs incurred after their final surgery. This highlights the long-term healthcare burden of single ventricle congenital heart disease.
Area of Science:
- Pediatric Cardiology
- Health Economics
- Congenital Heart Disease
Background:
- The Fontan procedure is a palliative surgery for single ventricle congenital heart disease.
- Long-term inpatient resource utilization and associated costs for Fontan patients are not well-defined.
- Understanding these costs is crucial for healthcare planning and resource allocation.
Purpose of the Study:
- To estimate the inpatient resource use and costs for Fontan patients from birth to adulthood.
- To identify factors influencing cost differences in Fontan patient care.
- To analyze the distribution of costs across different stages of Fontan patient management.
Main Methods:
- Linked inpatient costing records from four major Australian and New Zealand hospitals with Fontan patient data.
- Utilized data from July 1995 to September 2014 for 420 Fontan patients.
- Analyzed diagnoses including hypoplastic left heart syndrome, tricuspid atresia, and double inlet left ventricle.
Main Results:
- The mean total inpatient cost from birth to 18 years was estimated at $390,601, with 164 inpatient days.
- Costs during the staged procedures period (birth to Fontan completion) were $219,482 (82 days).
- Post-Fontan costs over 15 years were $146,820 (65 days), with over 40% of pediatric costs occurring after the last planned surgery.
Conclusions:
- Fontan patients represent a significant long-term inpatient resource demand.
- Costs are influenced by factors such as sex and specific diagnoses like hypoplastic left heart syndrome.
- A substantial portion of lifetime healthcare costs for Fontan patients arises in the post-palliative surgery phase.
Abstract:
We estimated the inpatient resource use for a Fontan patient from birth to adulthood and explored factors that might induce cost differences (2014 US dollar). Inpatient costing records from 4 hospitals with greatest numbers of Fontan patients in Australia and New Zealand were linked with the Fontan registry database. Inpatient records between July 1995 and September 2014 for 420 Fontan patients were linked, and the most frequent primary diagnoses were hypoplastic left heart syndrome (20.7%), tricuspid atresia (19.7%), and double inlet left ventricle (17.1%). The mean hospital cost for a Fontan patient from birth to 18 years of age was estimated to be $390,601 (95% confidence interval [CI] $264,703 to $516,499), corresponding to 164 (95% CI 98 to 231) inpatient days. The cost incurred from birth through to Fontan completion (the staged procedures period) was $219,482 (95% CI $202,410 to $236,553) and the cost thereafter over 15 years was $146,820 (95% CI $44,409 to $249,231), corresponding to 82 (95% CI 72 to 92) and 65 (95% CI 18 to 112) inpatient days, respectively. Costs were higher in male and hypoplastic left heart syndrome patients in the staged procedures period (p <0.001). Having fenestration was associated with higher costs in the staged procedures period (p <0.001) and lower cost after Fontan over 15 years (p = 0.66). In conclusion, patients with single ventricle congenital heart disease continue to demand considerable inpatient resources after the staged procedures period. Over 40% of the pediatric hospital costs for Fontan patients were estimated to occur after the last planned surgery.
More Related Videos
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Heart Failure VI: Adjunct Therapies

